Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. (SBFM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sbfm · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Sunshine Biopharma, Inc. (SBFM) measures how much investors pay for each dollar of the company's trailing earnings. SBFM's current PE ratio of N/A is calculated by dividing its stock price of $2.43 by its TTM earnings per share of -$12.31.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Sunshine Biopharma, Inc.You SBFM | $1M | N/A | — | -$12.31 |
 Acurx Pharmaceuticals, Inc. ACXP | $3M | N/A | — | -$5.31 |
 Biofrontera Inc. BFRI | $12M | N/A | — | -$1.04 |
 Check-Cap Ltd. CHEK | $11M | N/A | — | -$4.30 |
 Evoke Pharma, Inc. EVOK | $19M | N/A | — | -$2.81 |
 HCW Biologics Inc. HCWB | $3M | N/A | — | -$3.79 |
 Inspira Technologies Oxy B.H.N. Ltd. IINN | $45M | N/A | — | -$0.45 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-14.37 | — | |
2024-12-31 FY2024 | — | $-73.16 | — | |
2023-12-31 FY2023 | — | $-3702.58 | — | |
2022-12-31 FY2022 | — | $-35236.42 | — | |
2021-12-31 FY2021 | — | $-94934.71 | — | |
2020-12-31 FY2020 | — | $-32001.05 | — | |
2019-12-31 FY2019 | — | $-9380.18 | — | |
2018-12-31 FY2018 | — | $-1415.73 | — | |
2017-12-31 FY2017 | — | $-238.42 | — | |
2016-12-31 FY2016 | — | $0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Sunshine Biopharma, Inc. (SBFM) measures how much investors pay for each dollar of the company's trailing earnings. SBFM's current PE ratio of N/A is calculated by dividing its stock price of $2.43 by its TTM earnings per share of -$12.31.
Frequently asked questions
SBFM pe ratio · 6 questionsSBFM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.43 and TTM EPS of -$12.31. Data sourced from Financial Modeling Prep via SBFM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Sunshine Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09